Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Core Insights - Biofrontera has successfully launched the RhodoLED XL in June 2024, which has quickly gained traction in the US market for photodynamic therapy (PDT) of actinic keratoses [1][4][9] - The RhodoLED XL is FDA-approved for use with Ameluz® and features enhanced LED technology for larger treatment areas [1][4][5] Company Performance - Over 10% of dermatology offices using Ameluz® have already installed the RhodoLED XL, indicating strong market acceptance [2] - The company has installed 100 units of the RhodoLED XL since its launch, showcasing rapid adoption [4][9] Product Features - The RhodoLED XL allows for the treatment of larger surface areas in a single session, improving efficiency for healthcare providers and convenience for patients [5][10] - The lamp's design has received positive feedback for its maneuverability and adjustability, enhancing the quality of care [10] Market Context - Actinic keratosis (AK) is a prevalent pre-cancerous skin condition affecting approximately 58 million people in the US, with 13 million treatments performed in 2020 [3] - The introduction of the RhodoLED XL is positioned to address the significant market need for effective AK treatments [3][12]